RHOH and melanoma: This pH-responsive fusion protein was shown to selectively induce tumor infarction, delay growth in human breast xenografts [94], and, more recently, to induce growth reduction and tumor shrinkage in a mouse melanoma model with just 2.5–5 μg of tTF fusion protein [95].